MGMT and central nervous system cancer: Better therapeutic response towards alkylating agents has been attributed to O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation in glioma patients, particularly those with GBM subtype (Bobola et al., 2015).